{"Clinical Trial ID": "NCT00371345", "Intervention": ["INTERVENTION 1:", "- Her2/neu amplified tumour, 70 mg twice daily (BID) Dasatinib", "Participants with an amplified tumour-type human epidermal growth factor (Her2/neu) (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of estrogen receptor [ER]/progesterone receptor [PgR]) received oral dasatinib 70 mg twice daily (BID) for a total daily dose (TDD) of 140 mg.", "INTERVENTION 2:", "Her2/neu amplified tumour, 100 mg twice daily", "Participants with an amplified tumour-type human epidermal growth factor (Her2/neu) (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of estrogen receptor [ER]/progesterone receptor [PgR]) received oral 100 mg dasatinib twice daily (BID) for a total daily dose (TDD) of 200 mg."], "Eligibility": ["Incorporation criteria:", "Women 18 years of age or older", "Recidivant, locally advanced or metastatic breast cancer with ER/PR expression and/or Her2/neu overexpression", "A paraffin tissue block must be available.", "A Measurable Disease", "Previous chemotherapy with anthracycline and/or taxane (neoadjuvant, adjuvant or metastatic)", "0, 1 or 2 chemotherapy in the metastatic setting", "Adequate function of the organ", "- Exclusion criteria:", "A metastatic disease confined to bone only", "Metastasis of the symptomatic central nervous system (CNS)", "\u2022 Concomitant medical disorders that may increase the risk of toxicity", "Unable to take oral medicines"], "Results": ["Performance measures:", "Number of participants with an objective response", "The tumour response was evaluated using the RECIST criteria: PR = reduction of at least 30% of the sum of LD of all target lesions from the initial sum of LD, CR = disappearance of all non-target lesions.", "Duration: From the day of first treatment to week 25 or at the time of discontinuation of treatment under study.", "Results 1:", "- Arm/group title: Amplified tumour by Her2/Neu, 70 mg twice daily (BID) Dasatinib", "Description of the arm/group: Participants with human epidermal growth factor (Her2/neu)-type of amplified tumour (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of the estrogen receptor [ER]/progesterone receptor [PgR]) received orally 70 mg dasatinib twice daily (BID) for a total daily dose (TDD) of 140 mg.", "Total number of participants analysed: 15", "Type of measurement: Number", "Unit of measurement: participants 0", "Results 2:", "Title of the arm/group: Amplified tumour by Her2/Neu, 100 mg BID", "Description of the arm/group: Participants with human epidermal growth factor (Her2/neu)-type of amplified tumour (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of the estrogen receptor [ER]/progesterone receptor [PgR]) received orally 100 mg dasatinib twice daily (BID) for a total daily dose (TDD) of 200 mg.", "Total number of participants analysed: 9", "Type of measurement: Number", "Unit of measurement: participants 1"], "Adverse Events": ["Undesirable Events 1:", "Total: 20/70 (28.57 per cent)", "NAUSEA 2/70 (2.86%)", "VOIX 1/70 (1.43%)", "DIARRHOEA 2/70 (2.86%)", "ABDOMINAL PEACE 1/70 (1.43%)", "LOWER ABDOMINAL PAGIN 1/70 (1.43%)", "FATIGUE 2/70 (2.86%)", "PYREXIA 1/70 (1.43%)", "OEDEMA PERIPHERAL 1/70 (1.43%)", "GENERAL DETERIORATION OF PHYSICAL HEALTH 3/70 (4.29%)", "PNEUMONIA 1/70 (1.43%)", "SINUSITIS 1/70 (1.43%)", "- LOBAR PNEUMONIA 1/70 (1.43%)", "Adverse Events 2:", "- Yeah, that's right."]}